• LAST PRICE
    21.1700
  • TODAY'S CHANGE (%)
    Trending Down-0.2600 (-1.2133%)
  • Bid / Lots
    18.5000/ 1
  • Ask / Lots
    21.8700/ 1
  • Open / Previous Close
    21.5500 / 21.4300
  • Day Range
    Low 21.1600
    High 21.8900
  • 52 Week Range
    Low 7.4100
    High 24.1700
  • Volume
    260,061
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 21.43
TimeVolumeKURA
09:32 ET309021.2
09:34 ET40021.33
09:36 ET20021.33
09:38 ET10021.45
09:39 ET30021.52
09:43 ET10021.475
09:45 ET10021.6
09:48 ET40021.71
09:50 ET30021.75
09:52 ET210021.7
09:54 ET30021.73
09:56 ET222821.775
09:57 ET69221.715
10:01 ET78021.8
10:03 ET10021.825
10:06 ET21421.82
10:08 ET40021.79
10:10 ET81921.84
10:14 ET10021.84
10:15 ET10021.8
10:19 ET10021.78
10:21 ET20021.79
10:24 ET110021.87
10:30 ET60021.89
10:35 ET10021.83
10:44 ET10021.77
10:48 ET20021.76
10:53 ET24021.781
10:55 ET22521.8234
10:57 ET40021.77
11:00 ET31021.765
11:02 ET20021.77
11:06 ET10021.81
11:08 ET20021.84
11:11 ET10021.86
11:13 ET10021.85
11:15 ET41221.85
11:18 ET40021.86
11:27 ET10021.76
11:29 ET20021.78
11:33 ET50021.8
11:36 ET30021.8
11:42 ET10021.72
11:47 ET20021.67
11:51 ET210321.63
11:54 ET10021.63
12:07 ET20021.61
12:12 ET60021.59
12:16 ET10021.595
12:20 ET10021.605
12:21 ET10021.59
12:23 ET10021.57
12:25 ET30021.62
12:27 ET30021.59
12:34 ET20021.57
12:36 ET30021.55
12:41 ET10621.53
12:43 ET10021.54
12:45 ET22721.58
12:48 ET40021.57
12:54 ET20321.6
12:57 ET20021.61
12:59 ET10021.59
01:01 ET20021.55
01:03 ET65321.48
01:06 ET44821.52
01:08 ET30021.54
01:12 ET20021.5
01:21 ET10021.54
01:26 ET10021.535
01:28 ET20021.56
01:30 ET20021.605
01:32 ET20021.6
01:33 ET40021.56
01:37 ET20321.57
01:39 ET10021.52
01:42 ET20421.51
01:46 ET60421.52
01:48 ET1093621.41
01:50 ET35021.435
01:51 ET30021.46
01:55 ET20021.475
01:57 ET10021.5
02:00 ET30021.475
02:02 ET90021.45
02:04 ET10021.45
02:08 ET10021.43
02:09 ET10021.42
02:11 ET30021.42
02:13 ET34521.44
02:15 ET40021.44
02:18 ET20021.45
02:20 ET20021.44
02:22 ET12721.4469
02:24 ET31121.421
02:26 ET10021.42
02:27 ET20021.41
02:29 ET10021.39
02:31 ET10021.405
02:33 ET30021.385
02:38 ET10021.35
02:40 ET22521.33
02:44 ET110021.3
02:47 ET93521.33
02:51 ET10021.34
02:56 ET10021.34
02:58 ET30021.32
03:00 ET40021.325
03:02 ET30021.34
03:03 ET39821.295
03:05 ET40021.29
03:14 ET20021.27
03:16 ET30021.28
03:20 ET80021.29
03:21 ET20021.295
03:23 ET30021.28
03:25 ET40221.25
03:27 ET20021.265
03:30 ET20021.26
03:32 ET10021.27
03:34 ET70021.26
03:36 ET50721.23
03:38 ET70321.22
03:39 ET132721.25
03:41 ET130021.25
03:43 ET80021.26
03:45 ET81721.3
03:48 ET30021.28
03:50 ET142421.27
03:52 ET150021.24
03:54 ET112321.26
03:56 ET315721.17
03:57 ET599521.19
03:59 ET906221.17
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesKURA
Kura Oncology Inc
1.6B
-9.7x
---
United StatesEWTX
Edgewise Therapeutics Inc
1.6B
-11.1x
---
United StatesSNDX
Syndax Pharmaceuticals Inc
1.7B
-6.3x
---
United StatesSANA
Sana Biotechnology Inc
1.8B
-5.2x
---
United StatesKROS
Keros Therapeutics Inc
1.8B
-9.4x
---
United StatesNMRA
Neumora Therapeutics Inc
1.5B
-3.8x
---
As of 2024-05-24

Company Information

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a next-generation FTI, which demonstrates improved potency, pharmacokinetic and physicochemical properties relative to earlier FTI drug candidates.

Contact Information

Headquarters
12730 HIGH BLUFF DRIVE, SUITE 400SAN DIEGO, CA, United States 92130
Phone
858-500-8800
Fax
302-655-5049

Executives

Chairman of the Board, President, Chief Executive Officer
Troy Wilson
Chief Operating Officer
Kathleen Ford
Chief Medical Officer
Stephen Dale
Chief Commercial Officer
Brian Powl
Chief Legal Officer, Secretary
Teresa Bair

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$1.6B
Revenue (TTM)
$0.00
Shares Outstanding
76.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.95
EPS
$-2.18
Book Value
$5.34
P/E Ratio
-9.7x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.